Trial Search Results
Neuroblastoma Precision Trial
This proposal sets forth the platform for a Precision Medicine clinical trial through the New Approaches to Neuroblastoma Therapy (NANT) consortium. We plan to utilize NANT's established multi-institutional infrastructure and Translational Genomics Research Institute (TGen) GEMTM sequencing platform for acquisition and gene panel sequencing of relapsed biological specimens in rNB including those obtained from the bone, bone marrow or soft tissue.
Stanford is currently not accepting patients for this trial.
New Approaches to Neuroblastoma Therapy Consortium
Collaborator: Rising Tide Foundation
- Other: Gene panel sequencing of tumor specimens
- Patients must be ≥ 1 year and ≤ 30 years of age at study registration
- Patients must have had a diagnosis of neuroblastoma either by histological
verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow
with increased urinary catecholamines.
- Patients must have a history of high-risk neuroblastoma according to
- COG risk classification at the time of study registration. Patients must have at least
one of the following: Recurrent/progressive disease, Refractory disease, Persistent
- Patient must be willing to undergo a clinically indicated biopsy and meet at least one
of the following requirements: Bone biopsy, Soft tissue biopsy, Bone marrow biopsy and
- Patients must not be receiving any other anti-cancer agents or radiotherapy during the
- Patients with disease of any major organ system that would compromise their ability to
withstand biopsy procedures of soft tissue, bone and/or bone marrow.
- Patients who enroll and successfully receive a NANT Precision Report may not re-enroll
at a future time.
- Patient declines participation in NANT 2004-05, the NANT Biology Study.
Ages Eligible for Study
1 Year - 30 Years
Genders Eligible for Study